Hikma Pharmaceuticals (LON:HIK) Receives “Equal Weight” Rating from Barclays

Barclays reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note released on Monday, MarketBeat reports. Barclays currently has a GBX 2,000 ($25.31) price objective on the stock.

Separately, Berenberg Bank raised their target price on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.81) to GBX 2,000 ($25.31) and gave the company a hold rating in a research report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of GBX 2,068.75 ($26.18).

Hikma Pharmaceuticals Stock Performance

LON HIK opened at GBX 1,839 ($23.28) on Monday. The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. The firm has a market capitalization of £4.08 billion, a price-to-earnings ratio of 2,744.78, a P/E/G ratio of 2.38 and a beta of 0.45. The firm’s 50 day simple moving average is GBX 1,922.43 and its 200 day simple moving average is GBX 1,892.68. Hikma Pharmaceuticals has a 1 year low of GBX 1,711 ($21.66) and a 1 year high of GBX 2,222 ($28.12).

Hikma Pharmaceuticals Increases Dividend

The business also recently announced a dividend, which will be paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st will be given a $0.47 dividend. The ex-dividend date is Thursday, March 21st. This represents a yield of 1.86%. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 8,507.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.